Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

1. Townsend WM,Holroyd A,Pearce R,Mackinnon S,Naik P,Goldstone AH,Linch DC,Peggs KS,Thomson KJ,Singer M,Howell DC,Morris EC (2013) Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol, 161(4), 578 - 586. 10.1111/bjh.12294.
2. Quezada SA,Peggs KS (2013) Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer, 108(8), 1560 - 1565. 10.1038/bjc.2013.117.
3. Sellar RS,Peggs KS (2012) Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation. Future Oncol, 8(12), 1549 - 1565. 10.2217/fon.12.153.
4. Direkze S,Mansour M,Rodriguez-Justo M,Kibbler C,Gant V,Peggs KS (2012) Candida kefyr fungal enteritis following autologous BMT. Bone Marrow Transplant, 47(3), 465 - 466. 10.1038/bmt.2011.112.
5. Hockings C,Peggs K (2012) Life after allogeneic bone marrow transplant. Br J Hosp Med (Lond), 73(6), C93 - C96.
6. Sive JI,Thomson KJ,Morris EC,Ward KN,Peggs KS (2012) Adenoviremia has limited clinical impact in the majority of patients following alemtuzumab-based allogeneic stem cell transplantation in adults. Clin Infect Dis, 55(10), 1362 - 1370. 10.1093/cid/cis689.
7. Sellar RS,Peggs KS (2012) Therapeutic strategies for the prevention and treatment of cytomegalovirus infection. Expert Opin Biol Ther, 12(9), 1161 - 1172. 10.1517/14712598.2012.693471.
8. Sive J,Ardeshna KM,Cheesman S,le Grange F,Morris S,Nicholas C,Peggs K,Statham P,Goldstone AH (2012) Hotel-based ambulatory care for complex cancer patients: a review of the University College London Hospital experience. Leuk Lymphoma, 53(12), 2397 - 2404. 10.3109/10428194.2012.694430.
9. Moore S,Kayani I,Peggs K,Qian W,Lowry L,Thomson K,Linch DC,Ardeshna K (2012) Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. Br J Haematol, 157(5), 543 - 552. 10.1111/j.1365-2141.2012.09096.x.
10. Sellar RS,Ward KN,Thomson KJ,Peggs KS (2012) Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT. Bone Marrow Transplant, 47(11), 1482 - 1483. 10.1038/bmt.2012.46.
11. Sellar RS,Peggs KS (2012) The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy, 14(4), 391 - 400. 10.3109/14653249.2012.662769.
12. Thomson KJ,Kottaridis P,Cassoni A,Morris EC,Khwaja A,Linch DC,Chakraverty R,Peggs KS,Mackinnon S (2012) ALLOGENEIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE MYELOID LEUKEMIA: NO INCREASE IN RELAPSE WITH ALEMTUZUMAB-DEPLETED GRAFTS BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2), S339 - S340.
13. Nicholson E,Mackinnon S,Thomson KJ,Sudak J,Fielding AK,Kottaridis P,Peggs KS,Morris EC,Chakraverty R (2012) FAVORABLE OUTCOMES IN ELDERLY AND HIGH-RISK PATIENTS WITH AML AND MDS FOLLOWING T-CELL DEPLETED REDUCED INTENSITY CONDITIONED ALLOGENEIC STEM CELL TRANSPLANTATION BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18(2), S346 - S347.
14. Moore S,Peggs K,Thomson K,Lowry L,Ljubic A,Goldstone AH,Linch DC,Ardeshna KM (2012) Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy BRITISH JOURNAL OF HAEMATOLOGY, 156(1), 142 - 144. 10.1111/j.1365-2141.2011.08818.x.
15. Thomson KJ,Mackinnon S,Peggs KS (2012) CMV-specific cellular therapy for acute myeloid leukemia? Blood, 119(4), 1088 - 1090. 10.1182/blood-2011-10-383943.
16. Sellar RS,Peggs KS (2012) Management of multidrug-resistant viruses in the immunocompromised host. Br J Haematol, 156(5), 559 - 572. 10.1111/j.1365-2141.2011.08988.x.
17. Mohamedbhai SG,Edwards N,Morris EC,Mackinnon S,Thomson KJ,Peggs KS (2012) Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure. Br J Haematol, 156(4), 516 - 522. 10.1111/j.1365-2141.2011.08944.x.
18. Peggs KS,Quezada SA (2012) PD-1 blockade: promoting endogenous anti-tumor immunity. Expert Rev Anticancer Ther, 12(10), 1279 - 1282. 10.1586/era.12.109.
19. Richardson S,Khan I,Rawstron A,Sudak J,Edwards N,Verfuerth S,Fielding A,Goldstone A,Kottaridis P,Morris E,Benjamin R,Peggs K,Thomson K,Vandenberghe E,Mackinnon S,Chakraverty R (2011) Risk-stratified adoptive cellular therapy following allogeneic haematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia British Jouurnal of Haematology, In press.
20. Robinson SP,Luan J,Canals C,Peggs K,Le Gouill S,Nicolaus K,Milpied N,Jouet J,Briones J,Guilhot F,Finke J,Sureda A,Schmitz N (2011) REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: THE EBMT EXPERIENCE ANNALS OF ONCOLOGY, 22, 94 - 95.
21. Kothari J,Ljubic A,Peggs KS,Thomson K,Morris E,Virchis AE,Lambert J,Goldstone AH,Linch DC,Ardeshna KM (2011) Autologous Stem Cell Transplantation Using BEAM Conditioning Is Highly Effective in Patients with Follicular Lymphoma Regardless of Prior Rituximab Exposure BLOOD, 118(21), 886 - 886.
22. Thomson K,Kayani I,Ardeshna KM,Morris E,Hough R,Goldstone AH,Linch DC,Peggs KS (2011) Response-Adjusted Transplantation in Primary Resistant and Relapsed Hodgkin Lymphoma BLOOD, 118(21), 158 - 158.
23. Townsend W,Holroyd A,Pearce RM,Mackinnon S,Goldstone AH,Linch DC,Peggs KS,Thomson K,Singer M,Naik P,Howell D,Morris E (2011) A Simple Prognostic Score to Predict Short and Long-Term Survival Following ICU Admission in Critically III Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients: Improved Survival Following Reduced Intensity Conditioning BLOOD, 118(21), 70 - 71.
24. Peggs K (2011) The role of alemtuzumab in allogeneic stem cell transplantation IMMUNOLOGY, 135, 19 - 19.
25. Raj D,Peggs K,Pule M,Linch D,Davies M,Nathwani A (2011) Adoptive immunotherapy for patients with chronic lymphocytic leukaemia using a chimeric antigen receptor targeting CD23 HUMAN GENE THERAPY, 22(10), A120 - A121.
26. Peggs KS (2011) Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies. Expert Rev Anticancer Ther, 11(11), 1667 - 1670. 10.1586/era.11.159.
27. Quezada SA,Peggs KS (2011) Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities. Immunotherapy, 3(8), 915 - 917. 10.2217/imt.11.83.
28. Quezada SA,Peggs KS,Simpson TR,Allison JP (2011) Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev, 241(1), 104 - 118. 10.1111/j.1600-065X.2011.01007.x.
29. Peggs KS,Kayani I,Edwards N,Kottaridis P,Goldstone AH,Linch DC,Hough R,Morris EC,Fielding A,Chakraverty R,Thomson KJ,Mackinnon S (2011) Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol, 29(8), 971 - 978. 10.1200/JCO.2010.32.1711.
30. Roddie C,Peggs KS (2011) Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opin Biol Ther, 11(4), 473 - 487. 10.1517/14712598.2011.554811.
31. Peggs KS,Thomson K,Samuel E,Dyer G,Armoogum J,Chakraverty R,Pang K,Mackinnon S,Lowdell MW (2011) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis, 52(1), 49 - 57. 10.1093/cid/ciq042.
32. Moore S,Peggs K,Thomson K,Ljubic A,Goldstone AH,Linch DC,Ardeshna K (2011) AUTOLOGOUS STEM CELL TRANSPLANTATION REMAINS BENEFICIAL FOR PATIENTS RELAPSING AFTER R-CHOP AND WHO RESPOND TO SALVAGE CHEMOTHERAPY ANNALS OF ONCOLOGY, 22, 107 - 107.
33. Peggs KS,Kayani I,Thomson K,Morris E,Kottaridis P,Ardeshna KM,Fielding A,Hough R,Goldstone AH,Chakraverty R,Linch DC,Mackinnon S (2011) Positive Pre-Transplantation ([18-F]) FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma BLOOD, 118(21), 881 - 881.
34. Peggs KS,Quezada SA (2010) Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev Anticancer Ther, 10(11), 1697 - 1701. 10.1586/era.10.144.
35. Porter DL,Alyea EP,Antin JH,DeLima M,Estey E,Falkenburg JH,Hardy N,Kroeger N,Leis J,Levine J,Maloney DG,Peggs K,Rowe JM,Wayne AS,Giralt S,Bishop MR,van Besien K (2010) NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 16(11), 1467 - 1503. 10.1016/j.bbmt.2010.08.001.
36. Thomson KJ,Morris EC,Milligan D,Parker AN,Hunter AE,Cook G,Bloor AJ,Clark F,Kazmi M,Linch DC,Chakraverty R,Peggs KS,Mackinnon S (2010) T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol, 28(23), 3695 - 3700. 10.1200/JCO.2009.26.9100.
37. Chakraverty R,Orti G,Roughton M,Shen J,Fielding A,Kottaridis P,Milligan D,Collin M,Crawley C,Johnson P,Clark A,Parker A,Bloor A,Pettengell R,Snowden J,Pettitt A,Clark R,Hale G,Peggs K,Thomson K,Morris E,Mackinnon S (2010) Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood, 116(16), 3080 - 3088. 10.1182/blood-2010-05-286856.
38. Craddock C,Nagra S,Peniket A,Brookes C,Buckley L,Nikolousis E,Duncan N,Tauro S,Yin J,Liakopoulou E,Kottaridis P,Snowden J,Milligan D,Cook G,Tholouli E,Littlewood T,Peggs K,Vyas P,Clark F,Cook M,Mackinnon S,Russell N (2010) Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica, 95(6), 989 - 995. 10.3324/haematol.2009.013920.
39. Mead A,Thomson KJ,Morris EC,Mohamedbhai S,Orti G,Chakraverty R,Linch DC,Mackinnon S,Peggs KS (2010) HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced intensity conditioning BRITISH JOURNAL OF HAEMATOLOGY, 149, 21 - 21.
40. Lambert JR,Bomanji JB,Peggs KS,Thomson KJ,Chakraverty RK,Fielding AK,Kottaridis PD,Roughton M,Morris EC,Goldstone AH,Linch DC,Ell PJ,Mackinnon S (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood, 115(14), 2763 - 2768. 10.1182/blood-2009-11-255182.
41. Peggs KS,Thomson K,Morris E,Kottaridis P,Hough R,Goldstone A,Fielding A,Ardeshna K,Chakraverty R,Linch DC,Mackinnon S (2010) Donor lymphocyte infusions guided by PET-CT offer durable salvage in relapsed Hodgkin's lymphoma post-allogeneic transplantation BONE MARROW TRANSPLANTATION, 45, S42 - S42.
42. Orti G,Peggs K,Collin M,Clark R,Milligan D,Roddie H,Liakopoulou E,Crawley C,Clark A,Pettengel R,Chowdhry N,Roughton M,Snowden J,Morris E,Thomson K,Kottaridis P,Fielding A,Mackinnon S,Chakraverty R,UK Collaborative Grp (2010) Final results of UK multi-centre, phase II study of Campath-1h dose de-escalation prior to non-myeloablative hla-identical sibling stem cell transplantation BONE MARROW TRANSPLANTATION, 45, S55 - S55.
43. Thomson K,Morris E,Milligan D,Parker A,Hunter A,Cook G,Bloor A,Clark F,Kazmi M,Linch D,Chakraverty R,Peggs K,Mackinnon S (2010) T-cell depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma BONE MARROW TRANSPLANTATION, 45, S57 - S57.
44. Richardson S,Vandenberghe E,Benjamin R,Sudak J,Goldstone A,Thomson K,Morris E,Peggs K,Fielding A,Kottaridis P,MacKinnon S,Chakraverty R (2010) Reduced-intensity allografting with in vivo T-cell depletion is associated with a favourable outcome in chronic lymphocytic leukaemia BONE MARROW TRANSPLANTATION, 45, S238 - S238.
45. Mackinnon S,Lambert J,Bomanji J,Peggs K,Thomson K,Chakraverty R,Fielding A,Kottaridis P,Roughton M,Morris E,Goldstone A,Linch D,Ell P (2010) Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplant for lymphoma BONE MARROW TRANSPLANTATION, 45, S285 - S285.
46. Quezada SA,Simpson TR,Peggs KS,Merghoub T,Vider J,Fan X,Blasberg R,Yagita H,Muranski P,Antony PA,Restifo NP,Allison JP (2010) Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med, 207(3), 637 - 650. 10.1084/jem.20091918.
47. Mead AJ,Thomson KJ,Morris EC,Mohamedbhai S,Denovan S,Orti G,Fielding AK,Kottaridis PD,Hough R,Chakraverty R,Linch DC,Mackinnon S,Peggs KS (2010) HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood, 115(25), 5147 - 5153. 10.1182/blood-2010-01-265413.
48. Peggs KS,Quezada SA,Allison JP (2009) Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol, 157(1), 9 - 19. 10.1111/j.1365-2249.2009.03912.x.
49. Orti G,Fielding A,Kottaridis P,Morris E,Thomson K,Lowdell M,Peggs K,Mackinnon S,Chakraverty R (2009) Phase I study of high-stringency CD8-depletion of donor leukocyte transfusions following allogeneic haematopoietic stem cell transplantation. Transplantation, 88, 1312 - 1318.
50. Roddie C,Peggs K (2009) Hodgkin’s Lymphoma Medicine, 37(4), 208 - 211.